There's a 58% Chance of a Fed Rate Hike in October. These Are Stocks to Buy Anyway.

FedWatch probabilities put a 44.1% chance of a rate hike at the September meeting and 57.7% for late-October, but the article argues several stocks can hold up. UnitedHealth is up 20% YTD and posted ~54% YoY earnings growth in Q2 2026 with full-year guidance raised, making it viewed as rate-agnostic. JPMorgan reports Q2 net investment income of $25.6B (+10% YoY), which should rise with higher rates, while Chevron is up 20% YTD, supported by elevated fuel prices tied to the Iran war and sticky inflation.

Analysis

The market is likely overfocusing on the policy headline and underweighting the regime shift implied by a renewed hike path: stickier inflation, a steeper front-end repricing, and higher dispersion across financials. That is constructive for JPM and, to a lesser extent, CME as rate volatility supports trading activity, but the cleaner relative winner is JPM versus regional banks, because deposit costs and balance-sheet fragility hit smaller lenders faster than asset yields reprice.

UNH is the least macro-sensitive of the group and may actually benefit from the rotation into defensives if rate fears pressure long-duration growth. The bigger issue is not rates but whether the market is willing to pay a premium multiple for a business that is already in a recovery phase; if the turnaround is real, macro noise should be a buying opportunity rather than a thesis breaker.

CVX is the most conditional trade: it works only if higher rates are being driven by sustained energy inflation, not a broad growth scare. If crude cools, the rate-hike narrative collapses with it and CVX loses both the commodity tailwind and some of the inflation hedge bid. The contrarian miss is that a hike scare may be modestly negative for the average equity, but not all "beneficiaries" are equal; the best risk/reward is in pair trades that isolate funding-cost and yield-curve sensitivity rather than outright beta.

Key Decisions for Investors

• Long JPM / short KRE for the next 1-3 months to express large-cap deposit franchise strength versus regional-bank funding pressure; exit if regional NII trends improve faster than expected or if the Fed shifts back to a dovish path.
• Add UNH on weakness over a 6-18 month horizon as a defensive compounder; thesis breaks if medical cost ratios worsen or management cuts forward guidance.
• Tactical long CVX only if crude and inflation remain elevated for the next 1-3 months; pair against XLY or another consumer discretionary proxy to capture margin compression risk elsewhere in the economy.
• Use CME as a smaller volatility overlay rather than a core bet if policy uncertainty rises; best risk/reward is into rate-event weeks, not after the move is already priced.